


Your Partner in Scientific Discovery

For nearly a decade, ChromaDex has invested in cellular health research by supplying high quality and patented research materials, providing technical expertise, and commercializing the inventions of independent scientists around the world.

ChromaDex is the main owner and licensee of intellectual property for nicotinamide riboside (NR). In collaboration with our strategic partners, we manufacture NR as both an ingredient (NIAGEN®) and a finished dietary supplement product (TRU NIAGEN®) to the highest quality and standards.

As a result, we have received regulatory acceptance* in the United States, Canada, Australia, and Europe.



The ChromaDex External Research Program (CERP)

Since its founding in 2013, the ChromaDex External Research Program (CERP) has supplied NIAGEN[®], isotopically labeled NAD precursors and other ChromaDex material for preclinical and clinical research. Our team of scientists can share their analytical and regulatory expertise to support your successful design and execution of high-impact studies using these molecules. Applications are accepted on a rolling basis.

Please go to www.chromadex.com/cerp for more information.

225⁺

Research Collaborations

NIAGEN[®] has been independently researched by teams at Cambridge University, Northwestern University, Duke University, New York University, University of California, and many more around the world.

75⁺

Published Preclinical Studies

Many peer-reviewed published studies have investigated the effects of NIAGEN[®] on cells, mice, and other model organisms to help scientists understand the cellular and physiological effects of replenishing NAD⁺.

11⁺

Published Clinical Studies

The safety and efficacy of NIAGEN[®] has been studied in multiple peer-reviewed clinical studies, with more than 30 additional studies currently registered at:

www.clinicaltrials.gov.

CERP Research Published in High-Impact Journals

Cell

Fang, et al. (2014) Defective Mitophagy in XPA via PARP-1 Hyperactivation and NAD⁺/SIRT1 Reduction

Cell Metabolism

Shats et al. (2020) Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway

J of Clinical Investigation

Zhou et al. (2020) Boosting NAD Level Suppresses Inflammatory Activation of PBMC in Heart Failure


Setting the Industry Standard for Excellence in Collaborative Research

ChromaDex, Inc.

10900 Wilshire Boulevard, Suite 600, Los Angeles, CA 90034

(888) 642-4361 | cerp@chromadex.com | www.chromadex.com/cerp

Invested in Innovation



Talk to us about how we can support your inventorship and patent protection domestically and globally.

When you patent your work, your institution can license it to other organizations who can then commercialize it and put it to use in the marketplace. This generates licensing and royalty fees for you as the inventor.

ChromaDex vigorously supports and defends inventorship and the academic institutions where the work is performed. Over the past several years, ChromaDex has invested millions in licensing fees and millions more prosecuting defense of this important intellectual property.

NR & NAD⁺ Precursors**

USA	10,000,520	3027635	India
7,776,326	10,183,036	Australia	300117
8,106,184	10,280,190	2006238858	Japan
8,114,626	10,688,118	2014298629	6208352
8,197,807	10,689,411	2014342185	6509844
8,383,086	10,857,172	2016233247	Mexico
8,889,126	Canada	China	349969
9,000,147	2609633	1964627	South Africa
9,295,688	European Union	101360421	201603314
9,321,797	1755391	105636973	201706918
9,975,915	3006040	Hong Kong	201807736
10,000,519	1957086	1218918	

*Public Regulatory Acceptance for NIAGEN® and TRU NIAGEN® can be found at: <http://pages.truniagen.com/regulatory>

**Patents for other ChromaDex ingredients can be provided upon request.



**Nutritional Outlook's
2019 Best of the Industry:
Ingredient Supplier**

ChromaDex, Inc.

10900 Wilshire Boulevard, Suite 600, Los Angeles, CA 90034
(888) 642-4361 | cerp@chromadex.com | www.chromadex.com/cerp

Updated May 2021